Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma

Completed · Phase 2

Conditions studied: Oligoastrocytoma, Mixed, Anaplastic Oligodendroglioma

In brief

Rationale: Standard therapy for anaplastic oligodendrogliomas and mixed oligoastrocytomas includes radiation and chemotherapy. However, due to the potential long-term central nervous system toxicity from radiation, researchers speculate that it may be better to reserve radiation therapy for progressive disease. In addition, some patients with anaplastic oligodendroglioma and mixed oligoastrocytoma have unusually chemosensitive tumors. Previous research indicates that brain tumor patients with a deletion of the 1p chromosome have a higher response to the chemotherapy drug temozolomide.

Key facts

Study ID

NCT00362570

Run by

Ohio State University Comprehensive Cancer Center

People needed

1

Starts

2005-05-01

Expected to finish

2011-03-01

Last updated by the study team

2017-11-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• anaplastic oligodendroglioma or mixed oligoastrocytoma
• age > 18
• Karnofsky status > 70%
• adequate bone marrow, liver and renal function

You may not qualify if…

• prior chemotherapy or cranial irradiation

Where it is running

• Ohio State University — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.